Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Suicide Gene-Equipped t cells aim to make stem cell transplants safer

NCT ID NCT01494103

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-host disease (GvHD), a serious complication. The study enrolls people with blood cancers or immune disorders who lack a perfectly matched donor. The goal is to find a safe dose of these cells and see if they improve immune recovery without causing severe GvHD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iCaspase9-transduced T cells and AP1903
What this could lead to
If it works, this approach could help patients recover their immune system faster after a stem cell transplant while providing a safety switch to stop dangerous graft-versus-host disease.
What could go wrong
This is an early-phase trial with only 15 participants, so results may not apply broadly. The suicide gene may not activate fully, or the modified cells could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

15 people

The number who actually took part.

Start date

Nov 2011

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion Criteria at Time of Procurement: 1. Lack of a suitable conventional donor (i.e. 5/6 or 6/6 related, or 5/6 or 6/6 unrelated donor), or presence of a rapidly progressive disease not permitting time to identify an unrelated donor. 2. High risk disease in one of the following: * Myelodysplastic syndrome (MDS) in one of the following categories: RCMD with an IPSS-R of intermediate, poor, or very poor, RAEB-1, or RAEB-2 * Acute myeloid leukemia (AML) after first relapse or primary refractory disease * Chronic myelogenous leukemia (CML) in Chronic Phase 2 or greater, Accelerated Phase or Blast Crisis * Acute lymphoblastic leukemia (ALL) after first relapse or primary refractory disease, or High-Grade Non Hodgkin lymphoma (NHL) Stage III or IV after first relapse or primary refractory disease * Hemophagocytic lymphohistiocytosis (HLH) * Familial hemophagocytic lymphohistiocytosis (FLH) * Viral-associated hemophagocytic syndrome (VAHS) * T or NK cell lymphoproliferative syndrome * X-linked lymphoproliferative disease (XLP) Inclusion Criteria at Time of T Cell Infusion: 1. Engrafted with an absolute neutrophil count (ANC) \> 500 cells/µL 2. Greater than or equal to 50% donor chimerism in either peripheral blood or bone marrow, or relapse of their original disease 3. Life expectancy \> 30 days 4. Lansky/Karnofsky score greater than or equal to 60 5. Absence of severe renal disease (creatinine \> 2X upper limit of normal for age) 6. Absence of severe hepatic disease (direct bilirubin \> 3X upper limit of normal or SGOT \> 3X upper limit of normal) 7. Oxygen saturation \> 94% on room air 8. Patient/Guardian able to give informed consent 9. AP1903 available in sufficient quantities to allow for treatment of the patient Exclusion Criteria: Exclusion Criteria at Time of T Cell Infusion: 1. GvHD 2. Severe intercurrent infection 3. Pregnancy\* 4. Other investigational drugs in the prior 30 days * Pregnancy test only required for at-risk individuals, defined as female patients of childbearing potential who have received a reduced-intensity conditioning regimen.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

  • The Methodist Hospital

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.